Key Highlights

  • Shares closed up 8.00% at $29.70, trading on below-average volume.
  • BofA Securities raised its price target to $35 from $23, above both the $26.50 consensus and the $27.08 average target.
  • The upgrade follows a roughly 10% drop in the stock on October 6.
  • The company recently raised its 2026 Revenue guidance to a range of $1.03 billion to $1.04 billion.
  • A board member disclosed a 400,000-share sale at $30.33 in a recent filing.

BofA Securities Raises Target Well Above Consensus

Caris Life Sciences (NASDAQ:CAI) shares closed sharply higher after BofA Securities raised its price target on the stock to $35 from $23, a notable move above both the $26.50 consensus target and the $27.08 average analyst target. Caris Life Sciences is an AI-driven precision oncology company that uses whole exome, whole transcriptome, and whole genome sequencing, combined with artificial intelligence and machine learning, to power one of the industry's largest multimodal clinico-genomic databases.

Upgrade Follows a Sharp Pullback Earlier in the Week

The price-target increase comes after shares fell roughly 10% on October 6, and amid heavy insider selling activity, including a board member's disclosed sale of 400,000 shares at $30.33, filed as a publicly reported transaction. Despite the insider activity, BofA's more constructive valuation suggests the firm views the recent pullback as disconnected from the company's underlying growth trajectory.

Raised Revenue Guidance Supports the Bullish Case

The company recently reported second-quarter revenue of $263.7 million, up 45% year over year, and raised its 2026 revenue guidance to a range of $1.03 billion to $1.04 billion. That guidance increase has provided additional support for analysts revisiting their valuation models following the stock's recent volatility.

Shares Remain Below Their 12-Month High Despite the Gain

Healthcare was firmer in afternoon trading, adding a supportive sector backdrop, though biotech sentiment broadly remains cautious given elevated Treasury yields. Shares continue to trade below their 12-month high of $33.65 even after today's advance, suggesting room remains between the current price and BofA's new $35 target.